Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Profile of CS-747, a novel antiplatelet agent from Sankyo and Ube

March 22, 1999

First clinical experiences reported with S-1197 and its orally active prodrugs

March 22, 1999

Preliminary InTIME-II results point to equivalence of lanoteplase and alteplase in AMI

March 19, 1999

Novel platelet aggregation inhibitors developed by Chinese research team

March 18, 1999

Platelet P2T antagonists patented by Astra, useful as antithrombotics

March 17, 1999

rPSGL-Ig: novel P-selectin antagonist from Genetics Institute as adjunct to thrombolytic therapy

March 16, 1999

Eptifibatide lowers MI incidence, heart muscle injury in ACS patients

March 15, 1999

Genentech reports results on TNK-tPA from TIMI 10B and ASSENT 1 at ACC meeting

March 12, 1999

Heterocyclic factor Xa inhibitors disclosed by Zeneca

March 11, 1999

Results of phase II FROST study of lefradafiban presented at ACC

March 11, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...